CUE Cue Biopharma
- 1.420
- -0.080-5.33%
- 1.420
- 0.0000.00%
Cue Biopharma News
Cue Biopharma | 10-K: Annual report
Cue Biopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Cue Biopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer PASSERI DANIEL R
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Millar Kerri-Ann
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Suri Anish
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Sandercock Colin
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Levisetti Matteo
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Levisetti Matteo
Cue Biopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(4.98%)
Cue Biopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.2%)
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Director DRISCOLL FREDERICK W
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Garzone Pamela
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Kiener Peter A
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Morich Frank
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Verheyen Patrick
Cue Biopharma | 10-Q: Q3 2023 Earnings Report
Cue Biopharma | 8-K: Current report
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Suri Anish
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-CHIEF EXECUTIVE OFFICER PASSERI DANIEL R
Analysis
Price Target
No Data
